Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop) DOI Creative Commons
Irene Schiavetti, Alessio Signori,

Angela Albanese

и другие.

European Journal of Neurology, Год журнала: 2024, Номер 31(6)

Опубликована: Март 28, 2024

Abstract Background and purpose Cladribine tablets, a purine analogue antimetabolite, offer unique treatment regimen, involving short courses at the start of first second year, with no further needed in years 3 4. However, comprehensive evidence regarding patient outcomes beyond initial 24 months cladribine is limited. Methods This retrospective, multicenter study enrolled 204 patients multiple sclerosis who had completed 2‐year course treatment. The primary were therapeutic choices clinical disease activity assessed by annualized relapse rate after course. Results A total enrolled; most (75.4%) did not initiate new treatments 12 postcladribine. found significant reduction 12‐month follow‐up completion compared to year prior starting therapy (0.07 ± 0.25 vs. 0.82 0.80, p < 0.001). Furthermore, relapses during more likely therapies, whereas older less likely. safety profile was favorable, lymphopenia being registered adverse event. Conclusions provides insights into following It highlights cladribine's effectiveness reducing rates disability progression, reaffirming its favorable profile. Real‐world data, aligned previous reports, draw attention ocrelizumab natalizumab as common cladribine. larger, prospective studies for validation understanding long‐term impact are necessary.

Язык: Английский

Role of Immune Reconstitution Therapy with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in Older Patients DOI Creative Commons
Raed Alroughani, Jihad Inshasi, Samar Farouk

и другие.

Neurology and Therapy, Год журнала: 2025, Номер unknown

Опубликована: Май 17, 2025

Язык: Английский

Процитировано

0
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop) DOI Creative Commons
Irene Schiavetti, Alessio Signori,

Angela Albanese

и другие.

European Journal of Neurology, Год журнала: 2024, Номер 31(6)

Опубликована: Март 28, 2024

Abstract Background and purpose Cladribine tablets, a purine analogue antimetabolite, offer unique treatment regimen, involving short courses at the start of first second year, with no further needed in years 3 4. However, comprehensive evidence regarding patient outcomes beyond initial 24 months cladribine is limited. Methods This retrospective, multicenter study enrolled 204 patients multiple sclerosis who had completed 2‐year course treatment. The primary were therapeutic choices clinical disease activity assessed by annualized relapse rate after course. Results A total enrolled; most (75.4%) did not initiate new treatments 12 postcladribine. found significant reduction 12‐month follow‐up completion compared to year prior starting therapy (0.07 ± 0.25 vs. 0.82 0.80, p < 0.001). Furthermore, relapses during more likely therapies, whereas older less likely. safety profile was favorable, lymphopenia being registered adverse event. Conclusions provides insights into following It highlights cladribine's effectiveness reducing rates disability progression, reaffirming its favorable profile. Real‐world data, aligned previous reports, draw attention ocrelizumab natalizumab as common cladribine. larger, prospective studies for validation understanding long‐term impact are necessary.

Язык: Английский

Процитировано

2